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Objective: We aimed to evaluate the effects of gliclazide, metformin, and acarbose monotherapy on body
composition, fat distribution, and other cardiometabolic risk factors in patients with newly diagnosed
type 2 diabetes.
Methods: A total of 86 patients with newly diagnosed type 2 diabetes mellitus were randomly assigned
to receive gliclazide, metformin, or acarbose for 6 months. Dual-energy x-ray absorptiometry; abdominal
computed tomography scans; and measurements of adiponectin, leptin, and lipid levels were performed
before and after 6-month monodrug therapy.
Results: Blood glucose and glycosylated hemoglobin levels signiﬁcantly improved after 6 months of
monodrug therapy. During the 6 months of use of the 3 antidiabetes medications, the majority of
participants experienced fat mass loss and lean mass gain. Metformin monotherapy in patients with
newly diagnosed type 2 diabetes led to a signiﬁcant decrease in percent body fat (P ¼ 0.029) and body
fat mass (P ¼ 0.038). Levels of serum total cholesterol (P ¼ 0.004), triglycerides (P ¼ 0.014), and
adiponectin (P ¼ 0.001) took a favorable turn after metformin treatment. The 3 antidiabetes medications
caused no signiﬁcant change in abdominal fat distribution, waist circumstance, and blood pressure
during the 6 months.
Conclusions: Our results suggest metformin therapy in patients with newly diagnosed type 2 diabetes
can improve cardiometabolic risk markers. Moreover, body composition change induced by gliclazide
and acarbose was not likely to be simple fat deposition.
& 2013. The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
It is well known that obesity and diabetes mellitus have a close
relationship. The established pharmacotherapies for diabetes can
improve glycemic control and thus reduce the risk of diabetes-
related complications. However, weight gain is a frequent side
effect of antihyperglycemia therapy in patients with type 2 diabe-
tes mellitus.1–3 It has been shown that weight gain increases ther Inc.
tment of Endocrinology, East
0 Jimo Rd, Pudong District,
Open access under CC BY-NC-ND licerisk of cardiovascular disease, but the amount of body fat, rather
than the amount of excess body weight, may be a better indicator
for the health risks of type 2 diabetes mellitus and cardiovascular
disease.4 Although numerous clinical trials have evaluated the
body weight change induced by diabetes medications alone or in
combinations,5,6 the composition of body weight change in these
clinical trials has rarely been assessed.7,8 A study by Lee et al7
indicated that metformin may attenuate lean mass loss in older
men with diabetes, but oral glucose tolerance testing was not
performed in their study. Patients’ classiﬁcation was assessed by
prescription medication inventory without regard for the confused
effect of antihyperglycemic drug combinations. The study by
Rodrıguez-Moctezuma et al8 indicated that the administration of
metformin for 2 months improved the parameters of body
composition (ie, a decrease in body weight and fat with an
increase in lean mass) in patients without diabetes but with risk
factors for type 2 diabetes. Body composition in their study wasnse.
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tion was not involved.
Our study evaluated the effects of monodrug therapy on
cardiometabolic risk proﬁle (ie, body weight, body composition,
fat distribution, blood pressure, lipid proﬁle, and adipocytokines)
in patients with newly diagnosed type 2 diabetes. Sulfonylureas,
metformin, and α-glucosidase inhibitors are commonly used in the
treatment of patients with type 2 diabetes. We chose Diamicron
MR (Servier, Hawthorne,Victoria, Australia), Glucophage (Bristol-
Myers Squibb, New York, NY), and Precose (Bayer Healthcare
Pharmaceuticals, Wayne, NJ) as representatives of gliclazide,
metformin, and acarbose, respectively, according to the report
“Pharmaceutical Sales in the East China in 2009” by IMS Health.Patients and Methods
Patients
A total of 90 patients (drug-naive) with hyperglycemia (glyco-
sylated hemoglobin [HbA1c] 7%–10%)
9 were recruited from our
outpatient clinic between October 2010 and December 2011. They
were patients newly diagnosed with type 2 diabetes according to
the results of oral glucose tolerance test (World Health Organiza-
tion 1999 criteria). Patients with severe congestive heart failure
(ie, New York Heart Association functional class III–IV), liver
dysfunction (ie, aspartate aminotransferase and/or alanine amino-
transferase 41.5  upper limit of normal), and renal dysfunction
(ie, creatinine clearance o90 mL/min; creatinine clearance was
estimated from serum creatinine concentration using the
Cockcroft-Gault formula) were excluded.10 Patients with extraor-
dinary body weight (ie, body mass index o18.5 or 435 kg/m2)
and obvious dyslipidemia (ie, serum total cholesterol Z6.22
mmol/L, triglycerides Z2.26 mmol/L, and low-density lipoprotein
cholesterol Z4.14 mmol/L) were also excluded. Patients receiving
antidiabetes treatment before the study, or taking pharmacologic
agents known to affect carbohydrate homeostasis or inﬂuence
lipid levels were also excluded. No patient enrolled in this study
was diagnosed with type 1 diabetes mellitus.
After 4 weeks of diet treatment (energy intake 30 kcal/kg
ideal body weight per day), the enrolled patients were divided into
3 groups by simple randomization (random number generation in
Excel; Microsoft Corp, Redmond, WA). They were randomized to
take gliclazide, metformin, or acarbose. The initiated dose of each
group was according to the level of blood glucose. The maxi-
mum dose of gliclazide, metformin, and acarbose was 120 mg/d,
1,700 mg/d, and 300 mg/d, respectively. The therapeutic target
was deﬁned as HbA1c o7.0%. The study protocol was approved by
the Ethics Review Board of Tongji University. Written informed
consent was obtained from all participants and all of the proce-
dures were done in accordance with the Declaration of Helsinki
and relevant policies in China.Methods
All patients underwent both physical and laboratory examina-
tion at baseline (M0) and 6 months (M6) later. Waist circum-
ference was measured at the midpoint between the inferior costal
margin and the superior border of the iliac crest on the midaxillary
line. After an overnight fast for 10 to 12 hours, blood samples were
taken to test plasma glucose levels and lipids proﬁle. HbA1c was
analyzed by high-performance liquid chromatography. The con-
centrations of leptin and adiponectin were determined by ELISA
kits (Millipore Co, Ltd, Billerica, MA).Dual-energy x-ray absorptiometry (DEXA) measurement
Body composition was measured by DEXA scan (Lunar DPX-IQ;
GE Healthcare, Little Chalfont, Buckinghamshire, UK). Patients in
light clothes were measured and head-to-toe scans were per-
formed when they were lying down in a comfortable state on the
examination bed. The examination took approximately 15 to
20 minutes. Body composition, including body fat and lean mass,
was measured separately for arm, leg, trunk, and total. The results
were presented in kilograms for total body lean mass, fat mass,
and bone mineral content.Computed tomography (CT) measurement
The abdominal subcutaneous and visceral fat areas were
quantiﬁed by using a 64-channel multidetector CT scanner (Bril-
liance 64; Philips, Eindhoven, the Netherlands). With patients in a
supine position, a cross-sectional scan at 3-mm thickness was
obtained, centered at the L4 vertebral body to evaluate the
distribution of abdominal adipose tissue. The reorganized fat
density results ranged between 190 and 30 HU. The cross-
sectional subcutaneous fat boundary was deﬁned using a manual
cursor. Visceral adipose tissue area (VAT) was calculated as total
abdominal adipose tissue area minus subcutaneous adipose tissue
area (SAT).11 All scans were performed with the following param-
eters: 120 kV, 250 mA, thickness of 3 mm, increment of 1.5 mm,
pitch of 1.173. All imaging ﬁlms were read by 1 radiologist (Dr. S.
Yang). The original image was analyzed with the Mimics 10.0
software (Materialise Co, Leuven, Belgium).Statistical analysis
Comparisons of differences between normally distributed data
were carried out with a 2-tailed Student t test and 1-way ANOVA,
and non-normally distributed data with a Mann-Whitney U test
between groups. Categorical data were expressed as rates and
compared by a χ2 test. A P value o 0.05 was considered statisti-
cally signiﬁcant. For statistical analyses, SPSS version 13.0 (IBM-
SPSS Inc, Armonk, NY) was used.Results
Eighty-six patients (age range 35–75 years, mean (SD) 54.9
(9.8) years; 57 men and 29 women) completed the study. Two
patients withdrew because of side effects caused by metformin
and acarbose. Two patients were reluctant to follow-up. These
4 patients were excluded from the data analysis. There was no
signiﬁcant difference in baseline demographics, glycemic or lipid
parameters, body parameters, or other laboratory data among the
3 groups (Table).Glycemic control and lipid proﬁle
For the most part, the patients enrolled achieved glycemic
control during the 6 months. Mean (SD) HbA1c improved from M0
(8.40% [0.93%]) to M6 (6.46% [0.51%]) in the gliclazide group; from
M0 (8.07% [0.77%]) to M6 (6.37% [0.48%]) in the metformin group;
and from M0 (8.06% [0.82%] to M6 (6.44% [0.34%]) in the acarbose
group. Total cholesterol and triglyceride levels decreased signiﬁ-
cantly (P ¼ 0.004 and P ¼ 0.014, respectively) during the 6 months
in the metformin group. High-density lipoprotein cholesterol and
low-density lipoprotein cholesterol showed no signiﬁcant change
after treatment.
Table
Baseline and follow-up evaluation in patients with newly diagnosed type 2 diabetes mellitus after monodrug therapy*
Characteristic Gliclazide Metformin Acarbose
Baseline Follow-up Baseline Follow-up Baseline Follow-up
Male/female, n 21/9 21/9 18/11 18/11 18/9 18/9
Age, y 55.89 (10.5) 54.0 (10.3) 54.7 (8.9)
Height, cm 167.4 (7.8) 165.2 (8.5) 167.0 (8.8)
Body weight, kg 70.4 (11.7) 71.2 (11.0) 71.6 (12.7) 68.4 (12.2) 70.4 (11.7) 70.0 (12.1)
Waist, cm 86.4 (9.6) 86.7 (9.4) 88.1 (9.8) 87.5 (9.5) 88.4 (10.9) 88.4 (11.4)
SBP, mm Hg 125.1 (9.4) 127.1 (7.0) 126.4 (9.0) 128.2 (8.6) 126.7 (13.7) 127.2 (10.3)
DBP, mm Hg 76.3 (7.4) 75.1 (6.6) 74.9 (7.0) 76.1 (5.9) 75.0 (6.7) 73.3 (6.6)
FPG, mmol/L 8.82 (1.74) 6.59 (1.09)† 8.24 (1.23) 6.16 (0.98)‡ 8.86 (1.61) 6.36 (0.64)§
2hGlu, mmol/L 16.16 (3.28) 15.81 (2.83) 17.05 (3.06)
2hPG, mmol/L 10.70 (2.13)† 10.22 (1.36)‡ 10.09 (1.60)§
HbA1c, % 8.40 (0.93) 6.46 (0.51)† 8.07 (0.77) 6.37 (0.48)‡ 8.06 (0.82) 6.44 (0.34)§
TC, mmol/L 5.23 (1.02) 4.65 (0.90) 5.02 (0.85) 4.40 (0.70)‡ 4.95 (0.85) 4.41 (0.86)¶
TG, mmol/L 2.12 (1.25) 1.86 (1.19) 1.93 (0.53) 1.58 (0.55)|| 2.02 (0.97) 1.65 (0.51)
HDL-C, mmol/L 1.05 (0.33) 1.04 (0.32) 1.09 (0.32) 1.18 (0.35) 1.08 (0.24) 1.11 (0.37)
LDL-C, mmol/L 2.60 (0.68) 2.46 (0.75) 2.72 (0.67) 2.39 (0.65) 2.54 (0.60) 2.31 (0.71)
Leptin, ng/mL 5.65 (4.92) 6.38 (4.53) 7.31 (4.43) 6.01 (5.08) 6.16 (3.98) 5.69 (4.10
Adiponectin, μg/mL 2.55 (2.44) 3.34 (3.66) 3.03 (1.69) 5.38 (3.21)‡ 2.64 (1.67) 3.31 (2.10)
Drug dose/d 48.0 (14.9) mg 61.0 (14.7) mg† 1.00 (0.33) g 1.23 (0.43) g|| 138.0 (23.4) mg 181.5 (73.6) mg§
Body fat, % 29.02 (6.94) 27.54 (6.83) 30.95 (7.49) 26.50 (7.65)|| 28.01 (8.07) 26.68 (7.85)
Fat mass, kg 19.22 (5.68) 18.44 (5.67) 20.79 (6.45) 17.28 (6.12)|| 18.49 (6.13) 17.40 (5.77)
Lean mass, kg 46.56 (8.31) 48.22 (8.27) 45.62 (9.49) 46.04 (9.64) 46.54 (8.98) 46.93 (9.39)
BMC mass, kg 2.69 (0.55) 2.67 (0.55) 2.56 (0.61) 2.49 (0.56) 2.60 (0.59) 2.56 (0.55)
SAT, cm2 159.1 (72.9) 158.7 (73.7) 197.3 (78.5) 195.2 (79.6) 169.3 (60.8) 165.4 (53.2)
VAT, cm2 108.3 (58.1) 108.2 (56.7) 131.3 (57.4) 129.0 (56.8) 106.3 (42.8) 104.0 (38.2)
VAT/SAT 0.71 (0.22) 0.72 (0.23) 0.68 (0.19) 0.68 (0.19) 0.64 (0.13) 0.64 (0.15)
Waist ¼ waist circumstance; SBP ¼ systolic blood pressure; DBP ¼ diastolic blood pressure; FPG ¼ fasting plasma glucose; 2hGlu ¼ 2-hour plasma glucose in oral glucose
tolerance test; 2hPG ¼ 2-hour postprandial plasma glucose; HbA1c ¼ glycosylated hemoglobin; TC ¼ total cholesterol; TG ¼ triglycerides; HDL-C ¼ high-density
lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; SAT ¼ subcutaneous adipose tissue area; VAT ¼ visceral adipose tissue area.
nValues are presented as mean (SD). Patients were arrayed according to the time of study: 0 months (baseline) and 6 months (follow-up).
†Comparison between 6 months and 0 months in gliclazide group, P o 0.01.
‡Comparison between 6 months and 0 months in metformin group, P o 0.01.
§Comparison between 6 months and 0 months in acarbose group, P o 0.01.
||Comparison between 6 months and 0 months in metformin group, P o 0.05.
¶Comparison between 6 months and 0 months in acarbose group, P o 0.05.
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The waist circumference of each group showed no signiﬁcant
change during the 6 months. No signiﬁcant change in SAT and
VAT was observed during the 6 months of monodrug treatment.
As a result, the visceral to subcutaneous fat ratio remained
unchanged.Gliclazide
–5.0kg
–2.5kg
2.5kg
5.0kg
0
Metformin
body weight change
lean mass change
fat mass change
Acarbose
Figure. Boxplot indicating body weight change (black), lean mass change (gray),
and fat mass change (white). Comparison between gliclazide and metformin group
in body weight change (P ¼ 0.000), lean mass change (P ¼ 0.004), and fat mass
change (P ¼ 0.000); comparison between gliclazide and acarbose group in body
weight change (P ¼ 0.020), lean mass change (P ¼ 0.003), and fat mass change
(P ¼ 0.453); and comparison between metformin and acarbose group in body
weight change (P ¼ 0.000), lean mass change (P ¼ 0.872), and fat mass change
(P ¼ 0.000) .Body weight, fat mass, and lean mass (DEXA measurement)
During 6 months of therapy, gliclazide and acarbose were not
associated with signiﬁcant body weight change, and metformin
caused no signiﬁcant reduction in mean (SD) body weight (71.6
[12.7] kg at M0 vs 68.4 [12.2] kg at M6). As for body composition,
metformin led to a decrease in mean (SD) percent body fat (30.95%
[7.49%] at M0 vs 26.50% [7.65%] at M6; P ¼ 0.029) and fat mass
(20.79 [6.45] kg at M0 vs 17.28 [6.12] kg at M6; P ¼ 0.038),
but mean (SD) lean mass changed nonsigniﬁcantly from 45.62
(9.49) kg to 46.04 (9.64) kg. The body fat percent, fat mass, and
lean mass in the gliclazide and acarbose groups sustained no
signiﬁcant change during the 6 months. During 6-months of
follow-up, patients in the gliclazide group lost 1.5% total body
fat, the metformin group lost 4.5% total body fat, and the acarbose
group lost 1.3% total body fat. Compared with the other patients,
patients treated with metformin showed signiﬁcant changes in
body weight and body fat mass (Figure). The bone mineral content
of patients in each group sustained no signiﬁcant change during
the 6 months.Leptin and adiponectin concentrations
Mean (SD) serum fasting leptin had no signiﬁcant change (5.65
[4.92] ng/mL at M0 vs 6.38 [4.53] ng/mL at M6) and mean (SD)
adiponectin also had no signiﬁcant change (2.55 [2.44] μg/mL at
H. Wang et al. / Current Therapeutic Research 75 (2013) 88–92 91M0 vs 3.34 [3.66] μg/mL at M6) in the gliclazide group. Mean (SD)
serum fasting leptin had no signiﬁcant change (7.31 [4.43] ng/mL
at M0 vs 6.01 (5.08) ng/mL at M6) and mean (SD) adiponectin
signiﬁcantly increased from 3.03 (1.69) μg/mL to 5.38 (3.21) μg/mL
(P ¼ 0.001) in the metformin group. Mean (SD) serum fasting
leptin had no signiﬁcant change from M0 (6.16 [3.98] ng/mL) to
M6 (5.69 [4.10] ng/mL) and mean (SD) adiponectin also had
no signiﬁcant change from M0 (2.64 [1.67] μg/mL) to M6 (3.31
[2.10) μg/mL) in the acarbose group.Discussion
Increased body weight is associated with insulin resistance,
type 2 diabetes mellitus, and increases the risk of cardiovascular
disease.12–14 It is widely accepted that medication-induced weight
gain is an unfavorable result for patients with type 2 diabetes.
Obesity is a nutritional disorder characterized by abnormal accu-
mulation of body fat. The amount of body fat, rather than the
amount of excess body weight, may be a better indicator for the
health risks of type 2 diabetes mellitus and cardiovascular dis-
ease.4 The loss or gain of fat and lean mass that accompany body
weight change may not be equally effective in altering the
metabolic proﬁle of patients with type 2 diabetes mellitus.
Our study was designed to examine body composition changes
following monodrug therapy in patients with newly diagnosed
type 2 diabetes mellitus. We used DEXA, which is considered the
reference measure, because it is more accurate than bioelectrical
impedance for body fat measurement.15–17 We also used CT, which
is considered the gold-standard method to evaluate the abdominal
fat distribution.18 We chose metformin, gliclazide, and acarbose
because they are often-used antihyperglycemia drugs. During
6 months of monodrug treatment, metformin led to signiﬁcant
percent body fat and fat mass decreases, whereas percent body
fat and fat mass in the gliclazide and acarbose groups
remained unchanged. The SAT and VAT of each group sustained
no signiﬁcant change during the 6 months. In the study by
Rodrıguez-Moctezuma et al,8 2-month metformin use improved
the parameters of body composition (ie, a decrease in body weight
and fat with an increase in lean mass),8 although their study
design had some differences from ours. For example, the patients
in our study were newly diagnosed with type 2 diabetes mellitus,
whereas patients without diabetes but with risk factors for type
2 diabetes mellitus were enrolled in their study. Body composition
in our study was measured by DEXA, whereas body composition in
their study was measured by bioelectrical impedance and fat
distribution was not involved. Further, the length of follow-up
was 6 months in our study and 2 months in their study. Despite
these differences, our studies came to similar results. Serum total
cholesterol (P ¼ 0.004), triglycerides (P ¼ 0.014), and adiponectin
(P ¼ 0.001) levels took a favorable turn after metformin treatment
for 6 months. This indicates that metformin monotherapy in
patients with newly diagnosed type 2 diabetes can signiﬁcantly
improve cardiometabolic risk markers. Alain Simon’s study indi-
cated body fat mass was a better indicator of high coronary heart
disease risk than waist circumstance and body mass index.4
Furthermore, body fat percentage has a strong connection with
all-cause and cardiovascular mortality.19–21 During 6 months of
therapy, most patients in our study experienced fat mass loss and
lean mass gain, especially in the metformin group. Although there
was no statistically signiﬁcant difference in the gliclazide and
acarbose groups, the medication-induced change in body compo-
sition may not be unfavorable for the metabolic proﬁle in patients
with newly diagnosed type 2 diabetes. Several questions remain
unanswered: Would gliclazide and acarbose monotherapy lead to
similar results if the treatment time was increased? and, Wouldmonotherapy with either or both of those drugs reduce the risk of
cardiovascular disease events in patients with type 2 diabetes
mellitus? These need further study.Limitations
A limitation of our study is the small sample size, which did not
allow us to analyze the results by gender. Men and women are
signiﬁcantly different in the body fat percentage and serum levels
of leptin and adiponectin. A larger sample size may result in more
accurate results.
In our study, percent body fat and fat mass decreased after
6-month monotherapy with metformin. Lean mass had no sig-
niﬁcant change. Body composition in the gliclazide and acarbose
groups sustained no signiﬁcant change. Different follow-up
lengths may come to different results. It is necessary to prolong
the follow-up length and increase observation times.
DEXA has been shown to provide an accurate assessment of
body composition and has been used as reference methods for
comparison of other techniques, but it also has its limitations in
the assessment of body composition.16
During September 2010, the European Medicines Agency rec-
ommended that the drug rosiglitazone should be suspended in
Europe. The US Food and Drug Administration determined that the
drug could remain in the US market but made some signiﬁcant
restrictions. Rosiglitazone was recommended to be removed from
our hospital formulary in December 2010. Rosiglitazone works as
an insulin sensitizer in the thiazolidinedione class and was widely
used as glucose-lowering agent. Our hospital had no pioglitazone
drug in our formulary, so it was not brought into our study.Conclusions
Our study suggests metformin monotherapy in patients with
newly diagnosed type 2 diabetes can improve the parameters of
body composition and other cardiometabolic risk markers. More-
over, gliclazide- and acarbose-induced body composition change is
not likely to be simple fat deposition, and may have no unfavorable
effect on cardiometabolic risk proﬁle.Acknowledgments
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